Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Replacement Pancreatic Cells Could Be Treatment For Type 1 Diabetes

XTALKS NEWS

The researchers tested the encapsulated human cells in diabetic mice and found that the disease could be cured for six months, and the transplanted cells did not elicit an immune response.

Share this!

January 27, 2016 | by Sarah Massey, M.Sc.

Researchers at the Massachusetts Institute of Technology (MIT) and Boston Children’s Hospital, have designed a novel material for encapsulation of pancreatic cells, which may allow the cells to be transplanted into patients with type 1 diabetes. The researchers tested the encapsulated human cells in diabetic mice and found that the disease could be cured for six months, and the transplanted cells did not elicit an immune response.

Type 1 diabetes is an autoimmune disease in which the body’s immune system attacks and destroys the insulin-producing cells – known as islet cells – within the pancreas. Patients with type 1 diabetes must monitor their blood glucose levels throughout the day and ensure sugar levels stay in a healthy range by injecting insulin.

While researchers have previously tried to effectively cure the disease by replacing the damaged pancreatic islet cells with functional cells capable of monitoring blood sugar levels and secreting insulin, this treatment option has a definite drawback. The implanted islet cells often elicit an immune response, requiring those patients to take immunosuppressant medications for the duration of their lives.

According to Daniel Anderson, the Samuel A. Goldblith Associate Professor in MIT’s Department of Chemical Engineering, the islet cell encapsulation approach “has the potential to provide diabetics with a new pancreas that is protected from the immune system, which would allow them to control their blood sugar without taking drugs. That’s the dream.” Previous cell implants were encapsulated in alginate – a compound derived from a specific type of algae – which were ineffective due to their tendency to accumulate scar tissue.



In order to develop a better material for encapsulation, the researchers created a library of almost 800 alginate derivatives in the hope that one would be effective at protecting the cells while bypassing the immune system. “We decided to take an approach where you cast a very wide net and see what you can catch,” said Arturo Vegas, an assistant professor at Boston University who completed his postdoc MIT and Boston Children’s Hospital. “We made all these derivatives of alginate by attaching different small molecules to the polymer chain, in hopes that these small molecule modifications would somehow give it the ability to prevent recognition by the immune system.”

The researchers chose a compound known as triazole-thiomorpholine dioxide (TMTD) for further study in mice. They implanted the TMTD-encapsulated pancreatic islet cells into the abdominal cavity of diabetic mice bred to have a strong immune system. The implanted cells were able to control blood glucose levels for 174 days – the duration of the study.

“The really exciting part of this was being able to show, in an immune-competent mouse, that when encapsulated these cells do survive for a long period of time, at least six months,” said Omid Veiseh, a senior postdoc at the Koch Institute and Boston Children’s hospital. “The cells can sense glucose and secrete insulin in a controlled manner, alleviating the mice’s need for injected insulin.”

The next step is for this technology to be tested in other primates, and eventually humans. If results of further studies are positive, the encapsulation technique could be a viable treatment option for type 1 diabetes.

WATCH & PARTICIPATE IN THESE WEBINARS 


 

The Three Sins of GMP Executives

Regulatory Readiness for Clinical Trial Supplies


Keywords: Diabetes, Immune Response, Cell Therapy


| NEXT ARTICLE | MORE NEWS |

Share this with your colleagues!

READ THESE NEXT
Over 80 Pharmaceutical Companies Join Forces For Antibiotics R&D

January 26, 2016 - During the World Economic Forum in Switzerland last week, over 80 pharmaceutical companies – including major players like GlaxoSmithKline, Pfizer and Merck – pledged to devote more resources to the development of new antibiotics.


Shkreli and Schiller To Testify At Congressional Hearing On Drug Pricing

January 22, 2016 - Former Turing Pharma CEO Martin Shkreli, and Valeant Pharmaceutical’s interim CEO Howard Schiller are expected to participate in a Congressional hearing on pharmaceutical pricing set for January 26.


Two GlaxoSmithKline Scientists And Three Others Arrested After Attempting To Steal Biopharma Trade Secrets

January 22, 2016 - According to a statement released by the US Attorney’s Office of the Eastern District of Pennsylvania, five individuals – including two GlaxoSmithKline employees – have been charged with attempting to steal trade secrets from the biopharma giant.

LEAVE A COMMENT
 
Copyright © 2016-2017 Honeycomb Worldwide Inc.